EVO
$2.47
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing...
Recent News
Evotec Unveils “Horizon” Plan, Targets EUR 75M Savings and Guides 2026 EBITDA to EUR 0–40M
Evotec (NASDAQ:EVO) used a March 10, 2026 webcast to outline “Horizon,” the next phase of its multi-stage transformation initiative, and to provide preliminary unaudited 2025 results, 2026 guidance, and a medium-term financial framework through 2030. Horizon: a new operating model built on three pi
Evotec, Vistagen lay off staff; Immutep shares collapse on study failure
Evotec will cut 800 employees in its second layoff round since 2024. Elsewhere, Ultragenyx got a needed win and a twice-rejected cell therapy is getting an audience at the FDA.
Solvonis Therapeutics CEO on SVN-114 and PTSD market opportunity
Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company’s decision to select SVN-114 as the lead candidate in its post-traumatic stress disorder (PTSD) discovery programme and the opportunity the therapy could present if successfully developed. Tennyson explained that the decision followed pharmacological studies conducted by Evotec, which showed that SVN-114 provides balanced modulation across several important neurological systems. According to Tennyson, the compound influences serotonin, dopamine and noradrenaline receptors, which are all associated with mood, emotional processing and social behaviour. These systems play a significant role in the brain mechanisms involved in PTSD. He said the results were reviewed by the company’s scientific advisory committee, led by Professor David Nutt, which agreed that SVN-114 should be progressed as the lead candidate in the program. Tennyson explained that PTSD is a complex disorder involving multiple interconnected brain systems rather than a single pathway. The CEO highlighted the scale of the market opportunity, noting that PTSD affects more than 20 million people across the US, the UK and key European markets, while treatment options remain limited. Tennyson said: “If compounds like SVN-114 can demonstrate meaningful clinical benefits, then there's obviously a substantial opportunity to improve outcomes for patients and also to create value for the company and very importantly, for shareholders.” SVN-114 comes from a novel chemical series discovered by Solvonis and is supported by composition-of-matter patents, providing a strong intellectual property foundation for future development. The company is now focused on completing the remaining preclinical work required to support clinical development while pursuing non-dilutive grant funding in the UK and US. For more videos like this, visit the Proactive YouTube channel, give the video a like, subscribe to the channel and enable notifications so you never miss future updates. #SolvonisTherapeutics #AnthonyTennyson #SVN114 #PTSDTreatment #MentalHealthInnovation #DrugDevelopment #BiotechNews #Neuroscience #ClinicalDevelopment #PharmaInnovation
Is Evotec SE (EVO) One of the Best Debt-Free Penny Stocks to Buy Right Now?
Evotec SE (NASDAQ:EVO) is one of the best debt-free penny stocks to buy right now. On January 8, the company’s Seattle-based subsidiary Just-Evotec Biologics received a new grant from the Gates Foundation. The grant is to be used to enable global access to the company’s biotherapeutics utilizing Evotec Biologics’ molecular design suite. The Gates Foundation […]
Evotec (XTRA:EVT) Valuation Check After Recent Short Term Share Price Momentum
Evotec (XTRA:EVT) is back on investors’ radars after recent share price moves, with the stock showing a mix of short term gains and longer term declines that highlight contrasting performance snapshots. See our latest analysis for Evotec. The recent 7 day share price return of 14.08% and 30 day share price return of 20.28% contrast with a 1 year total shareholder return of 21.96% and 5 year total shareholder return of 78.72%. This suggests short term momentum against a weaker long term...